Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Intellia Therapeutics has received a consensus rating of "Moderate Buy" from eighteen research firms, with an average 12-month price target of $27.11.
• The company reported $14.25 million in revenue for the last quarter, exceeding expectations, and saw a year-over-year revenue increase of 104.3%.
• Insider trading activities included EVP Edward J. Dulac III selling 7,462 shares while Director William J. Chase acquired 100,000 shares, indicating differing confidence levels among executives.

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) have received an average rating of "Moderate Buy" from the eighteen brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have given a hold rating and eleven have assigned a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $27.1111.

NTLA has been the subject of several research reports. Guggenheim reissued a "buy" rating and issued a $14.00 target price on shares of Intellia Therapeutics in a report on Wednesday, August 13th. Wall Street Zen raised Intellia Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, September 6th. Chardan Capital reduced their target price on Intellia Therapeutics from $68.00 to $60.00 and set a "buy" rating for the company in a report on Monday, August 11th. HC Wainwright reduced their target price on Intellia Therapeutics from $30.00 to $25.00 and set a "buy" rating for the company in a report on Friday, August 8th. Finally, Wells Fargo & Company reissued an "overweight" rating and issued a $45.00 target price (down from $50.00) on shares of Intellia Therapeutics in a report on Friday, August 8th.

Insider Activity at Intellia Therapeutics

In related news, Director William J. Chase purchased 100,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 20th. The stock was purchased at an average cost of $10.03 per share, with a total value of $1,003,000.00. Following the completion of the acquisition, the director directly owned 134,693 shares in the company, valued at $1,350,970.79. This trade represents a 288.24% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Edward J. Dulac III sold 7,462 shares of the business's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $14.02, for a total transaction of $104,617.24. Following the completion of the transaction, the executive vice president directly owned 106,062 shares in the company, valued at $1,486,989.24. This represents a 6.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 12,534 shares of company stock valued at $153,837 in the last 90 days. Company insiders own 3.10% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in NTLA. GF Fund Management CO. LTD. purchased a new stake in Intellia Therapeutics in the 4th quarter valued at approximately $25,000. Headlands Technologies LLC purchased a new stake in shares of Intellia Therapeutics in the second quarter valued at approximately $26,000. Whipplewood Advisors LLC boosted its stake in shares of Intellia Therapeutics by 114,900.0% in the second quarter. Whipplewood Advisors LLC now owns 3,450 shares of the company's stock valued at $32,000 after buying an additional 3,447 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in Intellia Therapeutics by 56.4% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company's stock worth $33,000 after acquiring an additional 1,655 shares during the period. Finally, Harbour Investments Inc. raised its position in Intellia Therapeutics by 76.7% in the first quarter. Harbour Investments Inc. now owns 5,214 shares of the company's stock worth $37,000 after acquiring an additional 2,264 shares in the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Stock Performance

Shares of NASDAQ:NTLA traded up $0.14 on Friday, hitting $12.41. 6,849,962 shares of the company's stock were exchanged, compared to its average volume of 3,947,600. Intellia Therapeutics has a 1-year low of $5.90 and a 1-year high of $23.76. The company has a market capitalization of $1.33 billion, a PE ratio of -2.65 and a beta of 2.28. The firm's 50-day moving average is $11.68 and its 200 day moving average is $9.65.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.99) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.04. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.The business had revenue of $14.25 million during the quarter, compared to the consensus estimate of $12.26 million. During the same period in the previous year, the business earned ($1.52) EPS. The business's quarterly revenue was up 104.3% on a year-over-year basis. On average, analysts anticipate that Intellia Therapeutics will post -5.07 EPS for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.